Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Funding lifecycle and financial vocabulary

Rapidus 2nm Production Delay Reported: What It Means for Research Offices

Reports say Rapidus may delay 2nm production by about a year; the company says its fiscal 2027 target stands. What research offices should note.

Published 15 Nov 2026· 3 minute read

Ask CASRAI · free to try

Ask about this story

Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.

An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Reports published on 10 and 11 November 2026 say Rapidus, Japan’s government-backed chipmaker, is behind schedule on its 2nm process and may push commercial production back by about a year, from the second half of fiscal 2027 to fiscal 2028. Rapidus has not announced a new schedule and says it is still working toward its original target.

What was reported, and when

On 10 November 2026 Bloomberg (reporter Takashi Mochizuki) published “Japan’s Rapidus Is Said Likely to Miss Mass Production Deadline”. Citing people familiar with the matter, it said Rapidus had fallen behind its pledge to start mass production by March 2028 and had not yet produced functioning SRAM cells at 2nm, a step that was needed by summer. TrendForce’s summary of the Bloomberg report adds that the company is at least several months behind and is also working on dust and particle contamination in its cleanroom.

On 11 November 2026 Silicon Report relayed a report from Japan’s Jiji Press that Rapidus is considering delaying 2nm mass production by about one year, to fiscal 2028 (April 2028 to March 2029 in Japan’s April-to-March fiscal year). Jiji’s sources reportedly pointed to difficulty connecting transistors and integrating them with other components, which is hurting chip performance, and to slow progress on wafer yield.

What Rapidus says

A Rapidus spokesperson told Bloomberg the company remains fully committed to starting mass production in the second half of fiscal 2027, and the company declined to give technical details, calling them confidential. In the Jiji coverage Rapidus said it will continue to do everything possible to meet that target. The Edge Malaysia’s account of the same reporting adds that a government-commissioned expert panel reported in September that development is progressing, and that chairman Tetsuro Higashi said the previous month that the venture was on track.

Both delay accounts rest on unnamed sources and neither has been confirmed by Rapidus. Treat the one-year figure as a reported possibility, not an announced change.

Public funding behind the programme

According to TrendForce’s reading of the Bloomberg report, the Japanese government has committed more than 2 trillion yen to Rapidus so far, and a prolonged delay could put that support at risk. The Edge Malaysia likewise describes more than 2 trillion yen in state funding. Reports vary on the full amount, so this page uses only the lower figure that both sources share.

What this means for researchers, universities and research offices

The following is editorial interpretation, not reported fact. A publicly funded national chip programme runs on technical milestones, and a reported slip at one milestone is a reminder of how schedule risk reaches partners. Research offices and principal investigators who work with a state-backed programme, or with any consortium tied to a single process-node target, can usefully do three things:

  • Read the deliverable and milestone clauses in each agreement to see what happens to funding, publication rights and licence terms if a programme schedule moves; the principles are the same ones covered in diligence milestone and termination clauses.
  • Check whether any project depends on access to a specific fabrication line or node, and what the fallback is if that access arrives later than planned.
  • Treat advanced-chip collaborations as a research security matter as well as a scheduling one: see how export control classification and chip-level export controls apply when equipment, data or staff cross borders.

What to watch next

The decisive signals would be a formal schedule statement from Rapidus, a statement from the government ministry that funds the programme, or a published result for the SRAM milestone. Until one of these appears, the delay remains reported but unconfirmed.

Sources

  • Bloomberg, “Japan’s Rapidus Is Said Likely to Miss Mass Production Deadline”, 2026-11-10: https://www.bloomberg.com/news/articles/2026-11-10/japan-s-rapidus-is-said-likely-to-miss-mass-production-deadline (headline and summary checked 2026-11-15; full text is paywalled)
  • TrendForce, “Rapidus Reportedly Months Behind on 2nm SRAM Development, March 2028 Mass Production Target at Risk”, 2026-11-10: https://www.trendforce.com/news/2026/11/10/news-rapidus-reportedly-months-behind-on-2nm-sram-development-march-2028-mass-production-target-at-risk (checked 2026-11-15)
  • Silicon Report, “Rapidus considers one year delay for 2nm chip production”, 2026-11-11, relaying Jiji Press: https://www.siliconreport.com/rapidus-considers-one-year-delay-for-2nm-chip-production (checked 2026-11-15)
  • The Edge Malaysia, 10 November 2026 report on Rapidus: https://theedgemalaysia.com/node/825119 (checked 2026-11-15)
  • AI Weekly, “Rapidus Likely to Miss March 2028 Deadline for 2nm Chips”, 2026-11-11: https://aiweekly.co/alerts/rapidus-likely-to-miss-march-2028-deadline-for-2nm-chips (checked 2026-11-15)

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →